T helper 17 cells and B cells can work in concert to spark long-lasting protection against solid tumors, a research team at Winship Cancer Institute of Emory University found.
Imfinzi (durvalumab) has been accepted and granted Priority Review by the FDA for the treatment of patients with resectable, early-stage, and locally advanced (stages 2, 3, 4a) gastric and gastroesophageal junction cancers.
The European Commission approved Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
The National Cancer Institute approved the following clinical research studies last month.
The first large cancer screening/early detection initiative to be launched in 2025—the NCI-funded Vanguard study of multi-cancer detection tests—has started accruing patients through nine sites across the U.S.
On July 4, President Donald Trump signed into law “The One Big Beautiful Bill Act,” which is expected to deal a massive blow to Medicaid coverage and leave millions without insurance by instituting a work requirement for beneficiaries.
In a move that will have direct impact on approval of cancer drugs, George Francis Tidmarsh, an oncologist and a longtime pharmaceutical executive, was named director of the FDA Center for Drug Evaluation and Research.
NCI announced that the paylines for R01 grants for established and new investigators are expected to drop to the 4th percentile—a historic low for the institute.
Laura LoomerVinay PrasadRight-wing activist Laura Loomer is demanding Vinay Prasad’s ouster from FDA, calling him a “saboteur” and “trojan [sic] horse” of the administration’s “Make America Healthy Again” initiative.
A report from the nonpartisan Congressional Budget Office said that proposed cuts at NIH could lead to a decrease in the number of new drugs that come to market in the next three decades.
